85508-99-2

Usage

Uses

Used in Personal Care Products:
4-Bromo-3-methyl-isothiazol-5-ylamine is used as a preservative for personal care products to inhibit the growth of bacteria, fungi, and algae, thereby extending the shelf life and maintaining the quality of these products.
Used in Paints and Adhesives:
In the paint and adhesives industry, 4-Bromo-3-methyl-isothiazol-5-ylamine is used as a biocide to prevent microbial contamination, ensuring the stability and performance of the products during storage and application.
Used in Cooling Water Systems:
4-Bromo-3-methyl-isothiazol-5-ylamine is utilized as an algaecide and biocide in cooling water systems to control the growth of microorganisms, which can cause fouling, corrosion, and reduced heat transfer efficiency.
However, there have been concerns about the potential health hazards of 4-Bromo-3-methyl-isothiazol-5-ylamine, including its skin and respiratory irritant properties. As a result, regulations have been established to control its use and set maximum allowable concentrations in certain applications to ensure safety and minimize risks. Despite these concerns, 4-Bromo-3-methyl-isothiazol-5-ylamine remains an important and widely used chemical in various industries due to its effectiveness in preserving and protecting products from microbial contamination.

Upstream product

• 24340-76-9 3-methyl-5-aminothiazole 
• 71134-43-5 3-methyl-5-aminoisothiazole hydrochloride 

Downstream Products

• 1732-55-4 4,5-dibromo-3-methyl-isothiazole 
• 930-42-7 4-bromo-3-methylisothiazole 

Relevant academic research and scientific papers

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula II.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I), as follows: wherein R1, R2, R4, W, X, Y, and G, are defined herein.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III); wherein R1c, R2C, R4C, Wc, Yc, Zc and Gc, are defined herein.

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

Imidazopyrazines as protein kinase inhibitors

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

ANTICANCER COMPOUNDS

This invention features compounds having formula (I): wherein, R1, R 2,R3, R4, R6, R7, T, X, and Y are as defined herein. This invention also features a method for treating cancer. The method includes administrating to a subject in need thereof a compound of formula (I).